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Abstract
The development of a new generation of multifunctional biomaterials is a continual goal for the
field of materials science. The in vivo functional behaviour of a new fusion protein that combines
the mechanical properties of spider silk with the antimicrobial properties of hepcidin was addressed
in this study. This new chimeric protein, termed 6mer + hepcidin, fuses spider dragline consensus
sequences (6mer) and the antimicrobial peptide hepcidin, as we have recently described, with
retention of bactericidal activity and low cytotoxicity. In the present study, mouse subcutaneous
implants were studied to access the in vivo biological response to 6mer + hepcidin, which were
comparedwith controls of silk alone (6mer), polylactic–glycolic acid (PLGA) films and empty defects.
Along with visual observations, flow cytometry and histology analyses were used to determine the
number and type of inflammatory cells at the implantation site. The results show a mild to low
inflammatory reaction to the implanted materials and no apparent differences between the 6mer +
hepcidin films and the other experimental controls, demonstrating that the new fusion protein has
good in vivo biocompatibility, while maintaining antibiotic function.
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1. Introduction
Over the past few decades, natural polymers have been
extensively studied and tailored for potential use in the
design of new devices for medical applications, including
vascular (Park et al., 2009) and tendon (Pabbruwe et al.,
2010) grafts and sealants (Bessa et al., 2010; Janmey
et al., 2008). In the case of proteins such as collagen and
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fibrin, their main sources are animal tissues, viz. skin,
tendons (Chung et al., 2007; Hubbell, 2003) and serum
(Janmey et al., 2008). However, the use of materials
from animal origins has disadvantages, including the risk
of disease transmission and immune reactions (Janmey
et al., 2008) and batch-to-batch variations (Langer et al.,
2004; Romano et al., 2010). Some proteins such as
spider silks would be desirable, due to their mechanical
properties; however, they are not easy to obtain from
nature, unlike the case for gelatin and alginate. In the
case of Bombyx mori silkworm silk, sericulture allows for
a constant supply of silk from the textile industry that
has been extensively utilized in the medical suture field
(Omenetto et al., 2010). In the case of spider silk, the
supply of natural protein is scarce, since it is difficult
to breed spiders (Spiess et al., 2010). In recent years
genetically engineered spider silk has been prepared
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Figure 1. Amino acid sequence for the new chimeric protein, 6mer + hepcidin. The 6mer sequence is depicted in black, and grey
indicates the hepcidin domain. The TS restriction site was used to insert the hepcidin sequence
and studied for a range of fundamental and applied
biomaterials needs (Spiess et al., 2010), including cell
culture surfaces (Widhe et al., 2010), nerve regeneration
(Allmeling et al., 2006, 2008) and wound dressings
(Baoyong et al., 2010). The outstanding mechanical
properties of silks (Heim et al., 2010), together with
biocompatibility and slow biodegradation in vivo (Xu
et al., 1990) and Food and Drug Adminstration (FDA)
approval for silkworm silk biomaterials, are driving
interest in a broader range of silk-based biomaterials
for medical needs (Hardy et al., 2009).
Spider dragline silk is one of the many different
types of silk produced by some spiders and the core
filament is formed by two spidroin protein molecules,
the major ampullate spidroin protein 1 (MaSp1) and
protein 2 (MaSp2) (Mahoney et al., 1997). MaSp has two
chemically distinct blocks or peptide regions: hydrophilic
GGX motifs (G stands for glycine and X is mostly
glutamine) and hydrophobic poly-alanine (poly-A) motifs
(Hayashi et al., 1999). GGX motifs assume a helical
conformation, forming less crystalline and amorphous
regions with elastic properties (Beek et al., 2002), which
alternate with the poly-A motif crystalline regions,
characterized by tightly packed anti-parallel β-sheets
responsible for the stiffness of silk fibres (Sponner et al.,
2007). Additionally, MaSp1 protein produced by the
spider species Nephila clavipes is one of the most studied
silks via recombinant DNA technology (Rabotyagova
et al., 2009; Scheibel, 2004; Xiaa et al., 2010). MaSp1
production in heterologous expression systems, such as
Escherichia coli, has advantages over natural sources, since
these expression systems represent a constant source
of spider silk, providing sufficient amounts of protein
for study. Further, this genetic-engineering approach
provides a path for precise control over the amino acid
sequence in the protein, including the chain length and
the sequence chemistry. This approach also offers the
possibility of enriching the native sequence with other
protein motifs with specific bioactivities or functions,
thereby generating new chimeric proteins with selective
biological activity. Silk-based block copolymers have been
fused with different protein motifs, such as RGD, a cell-
binding domain known to improve cell adhesion, for
the design of tailored silk systems for gene delivery
(Numata et al., 2010). Also, dentin matrix protein and
bone sialoprotein motifs have also been combined with
spider silk block copolymers to improve osseointegration,
highlighting the potential of these bioengineered silk
protein-based biomaterials for tissue engineering (Gomes
et al., 2010; Huang et al., 2007).
In the present study the in vivo biological responses
to a new chimeric protein with antimicrobial features,
designated 6mer + hepcidin (Figure 1), were assessed.
The 6mer stands for a spider silk block copolymer formed
by six repeats of the MaSp1 consensus sequence. We
previously described the design of this fusion protein and
activity studies demonstrated that antimicrobial activity
of the chimeric protein was preserved when evaluated
against E. coli and Staphylococcus aureus. Cell viability
and proliferation studies also supported that there were
not obvious cytotoxic effects from the chimeric protein
on mammalian cells (Gomes et al., 2011). These data set
the stage for the current study, where in vivo responses
to the protein were addressed to further determine the
feasibility of this type of protein for new biomaterial
systems.
Hepcidin is a antimicrobial peptide expressed by the
liver (Krause et al., 2000) and different studies have
demonstrated its antibacterial activity against different
stains of Gram-positive (Gram+) and Gram-negative
(Gram−) bacteria, such as: Gram− E. coli ML35 strain
and Neisseria cinerea, and Gram+ S. aureus, S. epidermis,
S. carnosus, Bacillus cereus, B. megaterium, B. subtilis,
Micrococcus luteus and group B Streptococcus (Koliaraki
et al., 2008; Wallace et al., 2006; Zhang et al., 2005).
Besides being an antimicrobial peptide, hepcidin also
emerged as an important regulator of iron homeostasis,
acting as an iron regulatory hormone and behaving
as a negative regulator of intestinal iron absorption,
iron transport across the placenta and macrophage iron
release (Ganz, 2003). Besides many other functions,
iron is an important element in infections and many
pathogens have developed the ability to sequester
iron from host. Therefore, iron deficiency may limit
bacteria growth and inhibit the formation of biofilms
(Singh et al., 2002).
The role of hepcidin in iron metabolism was first
demonstrated when overexpression of mRNA coding for
hepcidin in the liver of iron-overloaded mice was reported
(Pigeon et al., 2001). Hepcidin mRNA overexpression by
hepatocytes was also observed after treatment of the
mice with lipopolyssacharide (LPS) (Ganz, 2003). A 25-
fold increase in hepcidin mRNA levels were found within
8 h after treatment with interleukin-6 (IL-6), a cytokine
produced by monocytes and macrophages exposed to
LPS (Nemeth et al., 2003). These studies showed that
hepcidin expression is regulated by iron as well as by
immune stimuli. Upon infection, hepcidin acts in a dual
way against bacteria, by reducing the amount of iron
available for bacteria growth and also by attacking the
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bacteria directly (Falzacappa et al., 2005). Hepcidin’s
dual antimicrobial role in the infectious process makes
it an attractive target in the design of biomaterials
for biomedical applications. These biomaterials could
be used in the design of a new generation of grafts
to reduce infections after surgery and to prevent the
formation of bacterial biofilms, a significant cause of
implant failure (Rohde et al., 2010; Schierholz et al.,
2002). Promising results were obtained in vitro with the
6mer + hepcidin (Gomes et al., 2011), where the potential
of a highly tailored multifunctional protein system for
biomaterials was described. The system combined the
mechanical features of silk protein and the antimicrobial
properties of hepcidin peptide. These in vitro results,
together with the role of hepcidin in inflammation, are
the starting point for the present in vivo study. Early
biological responses to 6mer + hepcidin films were
assessed, along with controls including polylactic–glycolic
acid (PLGA) films and silk alone (6mer), as well as empty
defects. PLGA is a synthetic polymer approved by the
Food and Drug Administration (FDA) for drug delivery
and diagnostic and other clinical and basic science
applications, such as cardiovascular disease, cancer,
vaccines and tissue engineering (Lu¨ et al., 2009). Films
were implanted subcutaneously in mice and responses
were assessed visually, via histology and with flow
cytometry analysis.
2. Materials and methods
2.1. Cloning
The design and cloning of the 6mer (Bini et al., 2006,
Rabotyagova et al., 2009) silk control, and the 6mer +
hepcidin (Gomes et al., 2011) sequences was described in
our previous studies. Briefly, a pET30a+ (Novagen, San
Diego, CA, USA) vector was used for the construction
of pET30L carrying the 6mer silk block co-polymer
coding sequence with a SpeI restriction site next to
it for further sequence insertions. The hepcidin cDNA
sequence was prepared by annealing synthetic single-
stranded oligonucleotides (Invitrogen, Carlsbad, CA,
USA) encoding for hepcidin. The resultant cDNA double-
strand sequence carried SpeI and NheI restriction sites
for insertion into the vector pET30L + 6mer. After
digestion with SpeI (R0133S, New England Biolabs,
Ipswich, MA, USA) and NheI (R0131S, New England
Biolabs), the hepcidin cDNA sequence was inserted
into pET30L + 6mer vector, using T4 DNA ligase
(M0202S, New England Biolabs). The ligation product
was transformed into Escherichia coli DH5α cells (18 258-
012, Invitrogen). Successful transformants were identified
by plating on agar containing 25 µg/ml kanamycin.
The presence of the hepcidin insert was confirmed
by DNA sequencing (Tufts Core Facility, Boston, MA,
USA).
2.2. Protein expression, purification and
characterization
2.2.1. Protein expression and purification
The constructs pET30L + 6mer and pET30L + 6mer
+ hepcidin were used to transform E. coli RY-3041,
a mutant strain of E. coli BLR(DE3) defective in the
expression of SlyD protein (Huang et al., 2003; Yan
et al., 2001). Bacteria were cultivated at 37 ◦C in
Hyper Broth (0107-S, Athens Enzyme Systems) with
25 µg/ml kanamycin (K1876, Sigma, St. Louis, MO, USA)
until OD600 = 0.9–1. Protein expression was induced
with isopropyl β-D-thiogalactoside (IPTG, 15 529 019,
Invitrogen) at a concentration of 0.5 mM. After 2 h the
cells were harvested by centrifugation at 6500 rpm and
the bacterial pellet was lysed in denaturating buffer
(100 mM NaH2PO4, 10 mM Tris–HCl, 8 M urea, pH 8.0)
and left overnight with stirring for complete cell lysis.
For removal of cell debris, the mixture was centrifuged at
11 000 rpm. The resultant protein solution was incubated
for 2 h with Ni-NTA resin (30 250, Qiagen, Valencia, CA,
USA) with stirring. The protein/Ni-NTA resin mixture
was loaded onto a glass Econo-column (Biorad, Hercules,
CA, USA). After washing several times with denaturating
buffer at pH 8 and pH 6.0, proteins were eluted with
denaturating buffer with pH 4.5. Eluted protein solutions
were dialysed first in a 20 mM sodium acetate buffer,
followed by extensive dialysis in Milli-Q (MQ) water, using
cellulose ester snake skin membranes with a 100–500 Da
molecular weight cut-off (131 054, Spectra/Por Biotech,
Rancho Dominguez, CA, USA) for salt removal. Finally,
the dialysed proteins were lyophilized.
2.2.2. SDS–PAGE electrophoresis
The purity of the 6mer and 6mer + hepcidin proteins
was verified by sodium dodecyl sulphate–polyacrylamide
gel (SDS–PAGE) electrophoresis, followed by colloidal
blue staining. Briefly, proteins were mixed with NuPAGE
LDS sample buffer (NP0007, Invitrogen) and heated at
80 ◦C for 10 min. The samples were loaded into a bis–tris
4–12% gel (NP0321BOX, Invitrogen) for electrophoresis
separation. Afterwards, the gels were stained with a
colloidal blue kit (LC6025, Invitrogen) for protein band
detection.
2.2.3. Amino acid composition analysis
Amino acid analysis was carried out at Yale University, W.
M. Keck Foundation Biotechnology Resource Laboratory
(New Haven, CT, USA) on a Hitachi L-8900 amino acid
analyser (Tokyo, Japan), following an overnight in vacuo
acid hydrolysis at 115 ◦C. The analyser uses an ion-
exchange column with a pH and temperature gradient
to separate the amino acids. EZChrome Elite for Hitachi
software was used to run the analyser, collect and finally
to analyse the data (table S1).
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2.2.4. MALDI–TOF and protein sequencing
Matrix-assisted laser desorption–time-of-flight (MALDI–
TOF; Voyager-DE Pro, Applied Biosystems, CA, USA)
and protein sequencing (ABI 494, Applied Biosystems,
CA, USA) were used to confirm protein identity and
both analyses were performed at the Tufts University
Core Protein Chemistry Facility (Boston, MA, USA).
For MALDI–TOF, samples were dissolved in water at
a concentration of 2 mg/ml. Protein sequencing was
carried out with samples extracted from the protein bands
observed by SDS–PAGE after electrophoresis and colloidal
blue staining.
2.3. Fabrication of protein films
Protein films were prepared by dissolving the lyophilized
6mer or 6mer + hepcidin proteins in MQ water to a final
concentration of 2% m/v. Then 60 µl each protein solution
was cast onto a non-adherent polystyrene surface and left
to dry at room temperature. After complete drying, the
films were treated with 90% v/v methanol solution for
30 min to induce β-sheet conformation, thereby inducing
insolubility of the proteins. With methanol treatment
there was an improvement in the mechanical properties
of the films as well as preventing immediate dissolution
in culture media or in vivo in contact with body fluids.
After methanol treatment, the films were left to dry for
3 days for methanol evaporation.
PLGA film controls were prepared by dissolving PLGA
with a molecular weight in the range 40–75 kDa
(P2191, Sigma) in dichloromethane in a 1:15 ratio. After
complete dissolution, 60 µl PLGA solution was cast onto
a polystyrene surface and left to dry at least for 2 days
for complete dichloromethane evaporation. PLGA is a
synthetic polymer that was selected as a control in the
present study as it is biocompatible and biodegradable
(Bala et al., 2004) and is approved by the FDA for use
in sutures, bone plates and drug delivery systems (Bala
et al., 2004; Mishra et al., 2008). For sterilization, the
PLGA, 6mer and 6mer + BSP films were treated with
70% v/v ethanol solution for 30 min and immediately
before implantation each film side was treated for 15 min
with ultraviolet (UV) light. Before implantation, the films
were hydrated with sterile phosphate-buffered saline
(PBS) for 15 min. The films had a final diameter of ca.
8 mm.
2.4. Grafting
All procedures were conducted under animal care
protocols approved by Tufts Institutional Animal Care and
Use Committee. Subcutaneous grafting was performed in
the back of balb/c female mice, 5–7 weeks old, purchased
from Charles River (Wilmington, MA, USA) breeding
laboratories. A total of 40 animals were used in this
study. The animals were divided into four groups of five
animals, three groups carrying the 6mer, 6mer+ hepcidin
and PLGA films, respectively, and a fourth control group,
formed with animals subjected to the same surgical
procedure but carrying no implant.
The animals were anaesthetized with isoflurane and
part of the back of each was shaved with an electric razor
and disinfected with 70% v/v ethanol solution. Under
anaesthesia and after disinfection, a longitudinal dorsal
incision, ca. 1 cm long, was prepared using fine scissors.
Grafts were inserted into a subcutaneous pocket between
the skin and muscular layers. A single test sample was
implanted in each animal. The incisions were closed with
polyester/Dacron suture line and the surgical wounds
were again disinfected with betadine. The incisions were
monitored, as were the animals, for atypical signals. The
animals were sacrificed by cervical dislocation after 2 and
6 weeks to retrieve the implanted materials and to check
for inflammatory responses. The implants, together with
the overlying tissue, were removed and processed for
flow cytometry and histology analysis, as described in the
following sections.
2.5. Flow cytometry analysis
2.5.1. Cell isolation
For cell isolation, the tissue surrounding the implant
was removed and minced with the help of scissors or
a scalpel. The minced tissue was digested in 2 mg/ml
collagenase IV (17 104 019, Invitrogen) and 1.2 U/ml
dispase (17 105 041, Invitrogen) solution, prepared in
PBS, for 2 h at 37 ◦C with occasional stirring. The
digestion mixture was centrifuged at 1500 rpm for 5 min
at 4 ◦C, the supernatant was removed and the pellet
was resuspended at ca. 106 cells/ml in flow cytometry
buffer [PBS supplemented with 0.5% v/v bovine serum
albumin (BSA)]. To eliminate undigested tissue, the
mixture was passed through a 100 µm pore cell strainer,
collected in a 50 ml Falcon tube and again centrifuged
at 1500 rpm for 5 min at 4 ◦C. To remove the red
blood cells, the cell pellet was resuspended in 5 ml lysis
buffered solution (containing NaCl 137 mM, Na2HPO4
8 mM, KH2PO4 1.46 mM, KCl 2.68 mM, in distilled water
at pH 7.0). After 4–5 min incubation, 20–30 ml PBS
was added to stop the reaction. The cell suspension
was centrifuged as before, followed by two washes
with flow cytometry buffer. Blocking was carried out by
suspending the cell pellets in PBS, followed by 15 min
incubation on ice in the presence of rat anti-mouse
FcRII/III antibody (clone 2.4G2, 553 141, BD Pharmingen,
Franklin Lakes, NJ, USA). The antibody reacts specifically
with a common epitope on the extracellular domains
of mouse Fcγ II/III receptors and blocks non-antigen-
specific binding of immunoglobulins to the Fcγ II, Fcγ III
and possibly Fcγ I receptors, in vitro and in vivo. After
spinning the cell pellet at 1500 rpm for 5 min at 4 ◦C, the
cells were resuspended in 500 µl flow cytometry buffer
and used for cell immunostaining for flow cytometry
analysis.
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2.5.2. Cell labelling
For antibody staining, 50 µl cell suspension prepared
as above was aliquoted and gently mixed with sec-
ond antibody solution and incubated on ice for around
30 min. Secondary antibodies were labelled with allo-
phycocyanine (APC), phycoerythrin (PE), AlexaFluor
and fluorescein isothiocyanate (FITC) fluorescence dyes.
After incubation with secondary antibody, the cells were
washed twice with flow cytometry buffer and resuspended
in 200–300 µl of the same buffer supplemented with
ethylenediaminetetra-acetic acid (EDTA; 431 788, Sigma)
to protect the cells until flow cytometry analysis. Brief
descriptions of the secondary antibodies used in this study
to assess biological responses to the implanted materials
are given below:
PE-conjugated CD14. (557 740, BD Pharmingen, San
Jose, CA, USA) antibody reacts with CD14 glycoprotein
expressed by cells of monocyte and macrophage lineages
and to a lesser extent by granulocytes. CD14 is a receptor
for lipopolysaccharide (LPS) complex, a component
of the outer membrane of Gram-negative bacteria.
After recognition of the LPS complex, cells from the
immune system rapidly engage in inflammatory defence
mechanisms, which in some cases can lead to septic shock
(Schu¨tt, 1999).
AlexaFluor-conjugated CD4. (557 667, BD Pharmingen)
antibody recognizes CD4 surface marker, a transmem-
brane glycoprotein expressed by developing thymocytes,
major histocompatibility class II restricted mature T lym-
phocytes, including T helper cells and immunosuppressive
T cells (Bowers et al., 1997), and a subset of natural killer
T cells (Bendelac, 1995). CD4 is critical in both thymo-
cyte development and T cell activation and the expression
of CD4 surface marker by T cells during development
induces its differentiation into T helper cells exclusively
(Bowers et al., 1997).
FITC-conjugated CD3. (555 274, BD Pharmingen) antibody
reacts with the CD3 component of T cell receptor
(TCR), a multimeric surface complex resulting from the
assembly of seven different proteins. The T cell receptor-
associated CD3 complex is expressed on many thymocytes
and mature T lymphocytes and is essential for antigen
recognition and the resulting specific immunity (Clevers
et al., 1988).
APC-conjugated CD25. (558 643, BD Pharmingen) anti-
body acts against the low-affinity CD25 subunit
(IL2 receptor-α), forming the interleukin-2 receptor (IL-
2R), a surface cell receptor expressed in activated T
and B lymphocytes. IL-2R recognizes the interleukin-2
molecule which triggers cell proliferation and the emer-
gence of effector T cells important for the full expression
of immune responses (Chao et al., 2002).
AlexaFluor-conjugated CD8a. (557 668, BD Pharmingen)
antibody recognizes the 38 kDa α and 34 kDa α′ chains
of the CD8 coreceptor, a T cell surface glycoprotein
expressed by the major histocompatibility class I restricted
cytotoxic T cells and involved in antigen recognition
by cytotoxic T lymphocytes. CD8, as CD4 coreceptor,
is critical for the development and activation of T cells
(Janeway, 1992).
2.5.3. Instrumentation
Analyses were performed in a four-colour FACSCalibur
instrument (Becton Dickinson, NJ, USA) equipped with
a 488 nm argon-ion laser and a 635 nm red diode laser,
and data were processed using FlowJo analysis software
(Tree Star, OR, USA).
2.6. Histological procedure
Samples were retrieved after 2 and 6 weeks of implan-
tation for histological examination. Immediately after
collection, the samples were immersed in a 4% forma-
lin buffer solution and sent for processing and staining
at the Tufts University Animal Pathology Core Labora-
tory. The samples were embedded in paraffin and 10 µm
sections were prepared. Haematoxylin and eosin (H&E)
staining was used.
2.7. Statistics
All statistical analyses were performed using SPSS 17.0
software. The Shapiro–Wilk test was used to assess
the normality of the data. To test for significant
differences between experimental groups (6mer +
hepcidin, 6mer, PLGA and empty controls), one-way
ANOVA was used in conjugation with Dunet’s T3 post hoc
test for multiple comparison. p < 0.05 was considered
statistically significant.
3. Results
3.1. Protein characterization
SDS–PAGE analysis of the proteins showed an apparent
molecular weight around 28 kDa for both the 6mer,
with an expected molecular weight of 21.8 kDa, and
the 6mer + hepcidin, with an expected molecular
weight of 23 kDa (Figure 2). In the case of the 6mer
+ hepcidin, higher molecular weight protein bands were
also observed, which correspond to dimers and multimers
as previously observed (Zhang et al., 2005). Amino acid
analysis confirmed the corrected composition of the
chimeric protein (6mer + hepcidin) and the control
(6mer). As expected, glycine and alanine were the most
abundant amino acids in both 6mer and 6mer + hepcidin
proteins. MALDI–TOF analysis confirmed protein identity
Copyright  2011 John Wiley & Sons, Ltd.
360
J Tissue Eng Regen Med 2012;6:
DOI: 10.1002/term
356–368.
S. Gomes et al.
Figure 2. SDS–PAGE gel electrophoresis showing two bands of around 28 kDa for 6mer and 6mer + hepcidin. Dimers and multimers
were also observed for the 6mer + hepcidin
and showed a peak at 20.9 kDa for the 6mer protein, a
value close to the expected molecular weight of 21.8 kDa.
For the 6mer + hepcidin, MALDI–TOF analysis showed a
peak at 22.9 kDa, a value very near to 23 k Da predicted
size. Finally, protein sequencing analysis confirmed the N-
terminal sequence for both the 6mer and 6mer + hepcidin
proteins.
3.2. Cell characterization by flow cytometry
analysis
All animals survived without visible signs of stress or
inflammation. After cell isolations from the implant sites,
five different surface markers were assessed for cell
types present in the implantation region after 2 and
6 weeks: CD4, CD8, CD14, CD3 and CD25. In Figure 3,
representative flow cytometry plots are shown for the
labelling, and these data were used to determine the
percentage of positive cells expressing the surface marker
of interest (Figure 4). Two weeks after grafting the CD3
marker had the lowest expression values in the range
6.8–12.4% for the empty controls and the 6mer films,
respectively. In Figure 4A no major differences betweens
the plots for the samples and the empty control were
found and statistical comparison showed no significant
differences (p < 0.05) between samples. CD4 showed the
highest expression values, with an average of 67.7%,
60.6%, 77.7% and 68.4% for the 6mer, PLGA, empty
control and 6mer + hepcidin, respectively (Figure 4A).
For the CD4 marker, the presence of a second population
of positive cells with high fluorescent levels was evident
from the flow cytometry plots in the figure. ANOVA
analysis for CD4 showed significant differences (p < 0.05)
between samples and Dunet’s T3 post hoc test for multiple
comparison showed significant differences between the
PLGA and empty controls. For CD25 antigen, ANOVA
analysis showed a significant difference between PLGA,
6mer and 6mer + hepcidin and the controls with no
implants.
After 6 weeks of implantation, flow cytometry analysis
showed an increase in the percentage of cells expressing
surface markers CD14, CD8, CD25 and CD3. For CD4,
marker expression increased only for the PLGA samples.
Figure 4B shows the presence of a second population
of positive cells that was not evident for the samples
collected after 2 weeks. Also, flow cytometry labelling
(Figure 3) showed an increase in fluorescence intensity
for most of the surface markers. As in the case of
the samples collected after 2 weeks, after 6 weeks CD3
showed the lowest percentage of positive cells, with 12%,
38.5%, 26.6% and 15.3% for the 6mer, PLGA, empty
control and 6mer + hepcidin, respectively. Again, CD4
antigen showed the highest expression for most samples,
with values in the range 51.5–71.7% for the 6mer and
empty control samples (Figure 4B). Statistical comparison
showed no significant differences between the different
samples for each marker. However, when comparing
expression values obtained for the same samples after 2
and 6 weeks, some significant differences were observed.
For CD4, a significant (p < 0.05) increase in expression
from 2 to 6 weeks for the 6mer and 6mer + hepcidin
samples was found. A significant increase in expression
was also observed for CD25 for the 6mer, PLGA and 6mer
+ hepcidin samples.
3.3. Histological characterization
Histological characterization with H&E staining was
also used to assess biological responses to the 6mer
+ hepcidin films and to compare this to the various
controls (6mer, PLGA and empty implants). After 2 weeks
a mild inflammatory reaction was detected around the
6mer, 6mer + hepcidin and PLGA implanted films, with
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Figure 3. Representative flow cytometry plots for surface markers. Positive cells for the surface markers are depicted in black, and
grey indicates the negative cell population
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Figure 4. Representative plots of one experiment for the expression of CD4, CD8, CD14, CD3 and CD25 surface markers for the
cells extracted from the region surrounding each implant sample at the end of 2 and 6 weeks. Numbers represent the average
percentage of positive cells for each marker. Grey indicates marker expression and black indicates the negative control, with no
secondary antibody added
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Figure 5. H&E staining of PLGA, 6mer and 6mer + hepcidin films and the empty control after 2 and 6 weeks of implantation.
Magnification, ×10. ∗, implant
fewer cells in the empty controls when compared to the
implanted films (Figure 5).
After 6 weeks in vivo, fewer cells could be observed in
the tissues surrounding the implants and in the empty
controls and a more localized cell response was observed.
Moreover, the formation of a fibrous capsule was not
detected for any of the implanted materials (Figure 5).
4. Discussion
The importance of antimicrobial peptides in the inflam-
mation process has been discussed previously (Hiemstra,
2006; Tecle et al., 2010; Zhang et al., 2005), function-
ing as chemotactic agent for monocytes and T cells or
involved in activating the acquired immune response
system (Grigat et al., 2007). These peptides are also
important elements in wound healing (Aarbiou et al.,
2004), stimulating the proliferation of fibroblasts and
epithelial cells (Aarbiou et al., 2002; Murphy et al., 1993)
and inducing neovasculogenesis (Chavakis et al., 2004)
and cytokine mobilization (Bals, 2000). In the specific
case of hepcidin, besides its direct antimicrobial activity
against pathogens, it is also a key element in controlling
plasma iron concentration. Due to its role in iron home-
ostasis, hepcidin is considered to be a crucial link between
host defence and iron metabolism (Ganz, 2006). During
the early stages of bacterial infections, the exposure of
monocytes and macrophages to LPS, a component of the
Gram-negative bacterial outer membrane, leads to the
secretion of different types of cytokine (Nemeth et al.,
2003). The cytokine IL-6 is secreted by monocytes and
macrophages (Amersfoort et al., 2003) and induces hep-
cidin synthesis by hepatocytes during the acute phase of
inflammation in mice and humans (Nemeth et al., 2004).
Hepcidin binds to ferroportin an iron transmembrane
transporter, which blocks iron efflux from hepatocytes in
the liver and macrophages and absorptive enterocytes in
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the small intestine (Vyoral et al., 2005). This binding leads
to the degradation of ferroportin, resulting in the trapping
of iron inside hepatocytes, macrophages and entero-
cytes, with a consequent decrease of available serum
iron (Vyoral et al., 2005). The decrease in blood iron
diminishes the availability of iron for invading microor-
ganisms. As mentioned previously, iron deprivation limits
bacterial growth and inhibits biofilm formation, favour-
ing the appearance of mobile individual forms, which are
vulnerable to host attack (Ganz, 2003). Therefore, hep-
cidin has an important role in the early stages of infection
and inflammation, exerting dual antimicrobial activity by
attacking bacteria directly and by reducing the amount of
available iron necessary for microbial metabolism. These
characteristics, together with its low cytotoxicity (Park
et al., 2001), make hepcidin a promising molecule for use
in the design of biomaterials with antimicrobial properties
to reduce the risk of infection after implantation.
However, this strong link between hepcidin and the
immune system can also elicit an undesired inflammatory
response to biomaterials carrying this molecule. For
instance, the binding of hepcidin to the ferroportin
receptor present in the cell membrane of macrophages
(Vyoral et al., 2005) can promote macrophage adhesion
to the implant surface, which could accelerate the
degradation of the implanted biomaterial and also lead
to an intensification of the host immune response. For
these reasons, and since the evaluation of tissue–material
responses are important in order to assess the suitability
of a new biomaterial for biomedical applications, this
study addresses the first stages of the inflammatory
response to 6mer + hepcidin films implanted in mice.
Flow cytometry analysis was used to access the expression
of five different surface markers, CD4, CD8, CD3, CD25
and CD14. These five different markers are specific for
different types of immune cells and were used to assess the
cellular response to the implanted films. Flow cytometry
assay was complemented with histology studies and
both analyses showed similar inflammatory responses
between the three polymers tested [6mer + hepcidin,
PLGA (an FDA-approved polymer) and 6mer] and the
empty controls.
Flow cytometry analysis provided a quantitative
evaluation of the inflammatory response through different
cell markers. CD4 marker had the highest expression
levels at both 2 and 6 weeks. As mentioned previously,
this marker is expressed by subgroups of T lymphocytes,
such as mature T helper and immunosuppressive T cells,
and also by natural killer cells. T helper cells activate
and direct other immune cells, such as cytotoxic T cells,
and maximize the bactericidal activity of macrophages
(Zhu et al., 2010). Furthermore, the presence of positive
cells for CD8, CD3, CD25 and CD14 was also observed,
mainly after 6 weeks, when these markers had stronger
expression. Activated CD8 positive cytotoxic T cells are
efficient and rapid killers of target cells (Jenkins et al.,
2010). These cells only become fully activated in the
presence of CD4 T cells and they exert their effect either
by releasing lytic granules, which carry molecules capable
of forming pores in the membrane of target cells, or by
inducing cell apoptosis (Ruiz et al., 2007). The detection
of a CD25-positive cell population showed the presence
of B and T lymphocytes, which are cells responsible
for the production of antibodies and for cell-mediated
immune responses, respectively (LeBien et al., 2008).
Additionally, CD14-positive cells were detected by flow
cytometry, which indicates monocytes, macrophages and
granulocytes. Macrophage and granulocytes play a role
in host inflammatory responses, forming the first line of
immune defence (Alba-Loureiro et al., 2007; Hasko´ et al.,
2007).
In conclusion, the flow cytometry results are in
concordance with the histology observations and both
analyses showed a mild or low inflammatory host response
to all of the implanted materials. Flow cytometry indicated
the presence of different types of immune cells at the
implant site and histological analysis showed these types
of cells around the implant. Additionally, except for CD4
in the PLGA films and empty controls, flow cytometry
analysis shows no significant differences in either the
number or type of inflammatory cells for the 6mer +
hepcidin films when compared with the 6mer, PLGA and
empty controls. Since similar responses were observed
for the implanted films and for the controls, we conclude
that the observed mild or low inflammatory response was
not caused by the implanted films. Also, these results
show that the host immune response is mild or low and
restricted to a local reaction, mainly after 6 weeks.
The in vivo behaviour of different silk implants has
been described. The inflammatory response induced after
intramuscular implantation of silk and silk–RGD films
in mice in comparison to polylactic acid (PLA) and
collagen films has been reported (Meinel et al., 2005).
The inflammatory response to the silk and silk–RGD
films was equivalent to, or less than, that observed for
collagen controls, and far less than to PLA film controls.
Minimal inflammation responses were observed for silk,
silk–RGD and collagen films after 6 weeks (Meinel et al.,
2005). For PLA films, the presence of granulomatous
inflammation was found based on the presence of
multinucleated giant cells and macrophages (Meinel et al.,
2005). Degradation of silk films was not observed over the
6 week period, while for collagen there was considerable
degradation and only remnants of these films detected
(Meinel et al., 2005). Recently, recombinant spider silk
films as a wound dressing biomaterial was evaluated
in rats (Baoyong et al., 2010). In vivo results showed
that, as a biomaterial, the recombinant spider silk films
had good biocompatibility and were able to induce skin
regeneration. For the silk films, the wound-healing extent
was 95–90% after 21 days (Baoyong et al., 2010). Other
studies also addressed the in vivo behaviour of silk-based
scaffolds functionalized with bioactive molecules, such
as bone morphogenetic protein 2 (BMP-2) (Kirker-Head
et al., 2007) and tissue growth factor (TGF-β) (Tang
et al., 2009). Although a considerable number of studies
addressed the in vitro and in vivo responses to silk-based
materials, to our knowledge these are the first results
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reporting the in vivo inflammatory response to a protein
graft, fabricated from a chimeric protein combining spider
silk with an antimicrobial peptide.
In the literature, the use of biomaterials incorporat-
ing antimicrobial peptides is scarce. Recently, Bombyx
mori silk fibroin films were modified with a cecropin B
antimicrobial peptide, through the carbodi-imide chem-
istry, showing satisfactory antimicrobial in vitro results
(Bai et al., 2008). Furthermore, crosslinked gelatin hydro-
gels for the delivery of lysozyme antimicrobial peptide
prevented the adherence of bacteria to valves used in car-
diac valve replacement (Kuijpers et al., 2000). Crosslinked
gelatin showed sustained release of lysozyme during 30 h
after implantation, while the lysozyme content in the
surrounding tissue was elevated for 50 h. Later a chemi-
cally crosslinked gelatin–chondroitin sulphate hydrogel
impregnated into Dacron grafts was used as a con-
trolled release system for the delivery of two antimicro-
bial peptides, lysozyme and recombinant thrombocidin,
a protein derived from human blood platelets (Kui-
jpers et al., 2000). The results showed that crosslinked
gelatin–chondroitin sulphate hydrogels had a higher load-
ing capacity for lysozyme and recombinant thrombocidin
than crosslinked gelatin hydrogels. Also, in vivo assess-
ments found that the hydrogels were biocompatible and
degraded almost completely after 18 weeks of implanta-
tion (Kuijpers et al., 2000).
Other studies have described the use of silk and other
natural origin-based scaffolds as delivery systems for
antibiotic molecules (Bai et al., 2008; Kilian et al., 2008).
However, in most cases the scaffolds are soaked in the
antibiotic solution and therefore uncontrolled desorption
of the immobilized species was observed (Beutner et al.,
2010).
Microbial infections are major concerns to the medical
community in cases of internal prostheses, cutaneous
dressings and other medical devices, such as contact
lenses and catheters. To prevent these problems, antibiotic
pre-operative prophylaxis and antibiotic local delivery are
used. However, even with the extensive use of antibiotics,
the frequency of implant-related infections continues to
be a major health care concern. Currently used methods
of pre-operative prophylaxis and antibiotic local delivery
have the major disadvantages of not assuring homoge-
neous delivery of the drug throughout the host body
and of favouring the appearance of antibiotic-resistant
strains (Campoccia et al., 2010). Also, the generalized
use of antibiotics can lead to the development of resis-
tant bacterial strains. Therefore, there remains an urgent
need to develop new biocompatible biomaterials with
antimicrobial properties, both to reduce the use of antibi-
otic drugs and to maintain localized release at the defect
site, both issues that can be addressed with the function-
alized antimicrobial biomaterial system addressed in the
present study.
5. Conclusions
In the present study, the biological responses to a new
chimeric protein, 6mer + hepcidin, with antimicrobial
activity (Gomes et al., 2011), were reported. Flow cytome-
try and histology results showed no significant differences
in the inflammatory responses between mice carrying the
6mer + hepcidin films and mice implanted with various
controls – PLGA, 6mer or empty defects. These results are
promising and give further support to the developing
new bioengineered biomaterials with antimicrobial prop-
erties that offer a path forward in reduction in the use
of antibiotics to prevent infection in implants. The 6mer
+ hepcidin and other future fusion proteins with antimi-
crobial properties may represent a new and promising
approach to the design of a new generation of multifunc-
tional biomaterials bioengineered to prevent the onset
of infections, to be biocompatible and to elicit tissue
integration during the tissue regeneration process.
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